Spaulding Clinical, a leading clinical research organization (CRO), is expanding its services to include ADME (absorption, distribution, metabolism, and excretion) clinical trials. This strategic addition further solidifies Spaulding Clinical’s commitment to delivering comprehensive solutions to pharmaceutical and biotechnology companies worldwide.
ADME studies are vital components of drug development, providing critical insights into the behavior of drugs within the human body. By measuring the absorption, distribution, metabolism, and excretion of a drug, these trials offer valuable data on its safety, efficacy, and pharmacokinetics.
“With the addition of ADME studies to our suite of services plus hired staff with over 60 years combined experience in conducting these trial types, Spaulding Clinical is positioned to better support our clients in making informed decisions during drug development,” said Cassandra Erato, CEO of Spaulding Clinical. “These trials play a pivotal role in understanding the behavior and fate of a drug in the body, allowing researchers to optimize dosage, assess potential drug-drug interactions, and enhance overall drug safety profiles.”
Spaulding Clinical’s state-of-the-art facilities, equipped with cutting-edge technology and staffed by highly trained professionals, provide an ideal environment for conducting ADME studies. The company’s extensive experience in conducting Phase I trials, combined with its commitment to scientific excellence and regulatory compliance, ensures the delivery of high-quality data to support the development and regulatory approval of new drugs.
Erato added: “Our clients rely on us for the fastest results in Phase I. Adding these services allows us to deliver the full package of Phase I studies in record time to help groundbreaking new therapies get to proof of concept faster.”
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
